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Replication of the genome is required at each cell division. It is effected by DNA polymerases synthesizing a new DNA strand with a sequence dictated by a template strand. Low error rates 
are ensured by the fidelity of base incorporation, proofreading capa-
bilities of the polymerases and surveillance by the DNA mismatch 
repair machinery. DNA replication in humans is largely performed 
by the polymerases Pol ε and Pol δ, which undertake leading and 
lagging strand synthesis, respectively1,2.
Uniquely among nuclear polymerases, both Pol ε and Pol δ have 
proofreading activities mediated by their exonuclease domains, 
which identify and remove mismatched bases1,3–5. Somatically 
acquired heterozygous missense mutations in the POLE or POLD1 
exonuclease domains found in some human cancers cause defective 
proofreading and, consequently, high burdens of somatic mutations 
with distinctive mutational signatures6–9. Cancers with POLE exo-
nuclease domain mutations show very high single-base substitution 
(SBS) mutation burdens whereas those with POLD1 exonuclease 
domain mutations show less elevated SBS burdens but are often 
associated with microsatellite instability8. Mutations generated by 
proofreading-defective POLE and POLD1 show marked replication 
strand bias consistent with their differential roles in leading and 
lagging strand synthesis1,2,8. Polymerases with these mutations also 
cause mutator phenotypes when engineered into yeast and mice10–15.
POLE and POLD1 exonuclease domain mutations can also be 
inherited through the germline, causing a rare autosomal domi-
nant familial cancer predisposition syndrome known as polymerase 
proofreading-associated polyposis (PPAP), characterized primarily 
by early-onset colorectal and endometrial tumors16–18. It is plausible 
that an increased somatic mutation rate underlies this cancer pre-
disposition, and high somatic mutation loads have been reported in 
the small number of neoplasms analyzed from such individuals16. 
However, whether the mutation rate is elevated in normal cells, or 
in neoplastic cells only, is not known. If elevated in normal cells, 
the magnitude of the increase, whether it is raised over the whole 
lifespan, the range of tissues and fraction of cells in each tissue it 
affects, and the impact of subsequent neoplastic change are impor-
tant questions to address in elucidating the pathogenesis of neoplas-
tic transformation.
Accrual of somatic mutations has been proposed as the pri-
mary biological mechanism underlying aging19–24. This hypothesis 
is based on the premises that (1) mutations accumulate through-
out life and (2) higher mutation loads cause widespread malfunc-
tion of cell biology19,21,22,24. Recent reports have confirmed that the 
somatic mutation burden in normal cells does increase during 
life in a more-or-less linear manner25–33, compatible with a causal 
role for somatic mutations in aging. However, somatic mutations 
could, in principle, accumulate without significant biological conse-
quences. Thus, study of individuals with inherited POLE or POLD1 
exonuclease domain mutations could provide insight into the wider 
biological consequences of elevated mutation burdens and the 
pathogenesis of aging.
Results
Clinical information and samples. Fourteen individuals, aged 
between 17 and 72 years and each carrying one of four differ-
ent germline exonuclease domain mutations in POLE or POLD1 
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(POLE L424V (n = 8), POLD1 S478N (n = 4), POLD1 L474P (n = 1) 
and POLD1 D316N (n = 1)), were studied. Eleven had a history of 
five or more colorectal adenomas, with age at first polyp diagnosis 
ranging from 15 to 58 years. Five were diagnosed with colorectal 
cancer, all before age 50 years, and all had a known family his-
tory of colorectal adenoma, colorectal cancer and/or other can-
cers. No other consistent phenotypic abnormalities were reported 
(Supplementary Table 1)18.
Mutagenesis in normal intestinal stem cells. The epithelial cell 
population of an intestinal crypt is a clone derived from a single 
ancestral crypt stem cell that existed <10 years before sampling34–37. 
Somatic mutations found in the large majority of cells in a crypt, 
and thus with a high variant allele fraction (VAF), recapitulate the 
set of mutations present in that ancestral cell28. Thus, to investigate 
somatic mutation burdens and rates in normal cells from POLE and 
POLD1 germline mutation carriers, 109 normal intestinal crypts 
(colorectum, n = 85; ileum, n = 10; duodenum, n = 14) were indi-
vidually isolated by laser-capture microdissection from biopsy and 
surgical resection samples of 13 individuals and whole-genome 
sequenced (WGS) (median 33.5-fold coverage) (Methods, 
Supplementary Note and Supplementary Table 2).
Somatic SBS burdens in the seven individuals with POLE L424V 
and four with POLD1 S478N correlated with age, indicating that 
mutation accumulation is likely to be continuous through life, linear 
and at similar rates in each individual carrying the same mutation 
(linear mixed-effects model R2 = 0.87; Supplementary Note). Crypts 
from individuals with POLE L424V showed an average SBS muta-
tion rate of 331 per year (linear mixed-effects model 95% confidence 
interval (CI) 259–403, P = 10−12) (Fig. 1a,b and Supplementary 
Note). The POLD1 S478N germline mutations were associated with 
an SBS rate of 152 per year (linear mixed-effects model 95% CI 
128–176, P = 10−17), and POLD1 D316N and L474P were associated 
with an SBS rate of 58 per year (linear mixed-effects model 95% 
CI 51–65, P = 10−22). By comparison, intestinal crypts from healthy 
individuals acquire 49 SBS per year28 (linear mixed-effects model 
95% CI 46–52, P = 10−36). Therefore increased somatic SBS rates are 
present in all normal intestinal cells of individuals with POLE or 
POLD1 germline mutations (Fig. 1), although there are differences 
in mutation rates between POLE (~sevenfold higher than normal 
individuals) and POLD1 (up to threefold higher) germline muta-
tions, and between different POLD1 mutations. Indeed, individuals 
with POLD1 D316N and L474P exhibited relatively modest eleva-
tions of SBS rates (~1.2-fold). There was also evidence of differences 
in SBS rates between the seven individuals with POLE L424V, sug-
gesting the existence of genetic and/or environmental modifiers of 
mutation rate (Fig. 1b and Supplementary Note).
Small insertion and deletion (ID) mutation rates in normal 
intestinal crypts were also elevated in individuals with germline 
POLE/POLD1 mutations, with rates of 13 per year (POLE L424V), 
44 per year (POLD1 S478N) and 12 per year (POLD1 D316N 
and POLD1 L474P) (linear mixed-effects model, 95% CI 10–16, 
35–53, 9–16, P = 10−10, P = 10−13 and P = 10−9, respectively). These 
are all substantially above the expected rate of one per year in 
individuals without POLE or POLD1 mutations28 (Fig. 1d and 
Supplementary Note).
Thus, in the normal intestinal crypt, POLE germline mutations 
generally confer greater increases in SBS mutation rates than POLD1 
mutations, whereas POLD1 mutations confer elevations in ID muta-
tion rates larger than or similar to POLE (Fig. 1e). These relative 
differences in SBS and ID mutation rates are consistent with previ-
ous findings in cancer genomes and experimental systems6,8,11,38–40. 
It is noteworthy that the SBS and/or ID mutation burdens in nor-
mal intestinal crypts from middle-aged and older individuals with 
germline polymerase mutations are higher than those observed in 
many human cancers41.
With the exception of one individual who had been treated with 
oxaliplatin for colorectal cancer and one with an incidental find-
ing of mosaic trisomy of the X chromosome (47 XXX) (Extended 
Data Figs. 1a and 2), copy number changes and rearrangements 
were rare, occurring at a prevalence similar to normal crypts from 
normal individuals (Supplementary Table 2). Reductions in telo-
mere length with age also occurred at rates similar to those of nor-
mal crypts from healthy individuals (Supplementary Table 2 and 
Supplementary Note).
Elevated genome-wide mutation burdens are associated with 
increases in protein-coding mutations (Extended Data Fig. 3a). 
These include nonsense and frameshift changes that are likely to 
impair protein function (Extended Data Fig. 3a). There was a 
greater increase in nonsense mutations (~sevenfold) compared to 
missense or synonymous mutations (~four- and ~threefold, respec-
tively), which is due to the specific mutational signatures present42. 
There was also an increase in potential cancer ‘driver’ mutation bur-
den compared with normal crypts from normal individuals (20/109 
versus 26/445, P = 0.00005, chi-squared test; Extended Data Fig. 3b 
and Supplementary Table 3). However, this was broadly compatible 
with the increase in overall load and the spectrum of coding muta-
tions in the colon (Extended Data Fig. 3c).
Crypt-like structures from six colorectal adenomas and one car-
cinoma from individuals with germline POLE or POLD1 mutations 
were also microdissected and sequenced. SBS and ID burdens were 
considerably higher than in normal crypts from the same indi-
viduals sampled at the same time (Fig. 1e,f), albeit with substantial 
variation between lesions. Therefore, increases in SBS and ID muta-
tion rates are associated with conversion from a normal crypt to 
an adenoma or cancer crypt in individuals with POLE or POLD1 
germline mutations, a pattern similar to that observed in healthy 
individuals43,44.
Mutational signatures. Eleven SBS mutational signatures were 
observed in normal intestinal crypts from individuals with POLE 
and POLD1 germline mutations (Fig. 2a–c and Extended Data 
Fig. 4). Nine have been previously reported: SBS1, SBS5, SBS10a, 
SBS10b, SBS17b, SBS28, SBS35, SBS88 and SBS89 (https://cancer.
sanger.ac.uk/cosmic/signatures)9,28. SBS1 (characterized by C>T 
substitutions at NCG trinucleotides and probably due to deamina-
tion of 5-methylcytosine) and SBS5 (of unknown etiology) are found 
in all normal intestinal crypts from healthy individuals, where they 
accumulate in a more-or-less linear manner with age7,9,28,45. SBS88 
and SBS89 are found in normal intestinal crypts from some healthy 
individuals and are predominantly acquired during childhood28,46. 
SBS88 is likely due to colibactin, a mutagenic product of a strain 
of Escherichia coli sometimes present in the colon microbiome47. 
SBS10a, SBS10b and SBS28 were previously found in the subsets 
of colorectal, endometrial and other cancer types with somatically 
acquired POLE mutations7,9 (Fig. 2a). Two therapy-associated sig-
natures were identified: an SBS35-like signature associated with 
platinum-based chemotherapy9,48 in an individual treated with 
oxaliplatin (Fig. 2c and Extended Data Fig. 1b–e), and a signature 
characterized predominantly by T>G mutations (SBS17b-like) 
in an individual treated with capecitabine48,49(Fig. 2f). Two previ-
ously unreported mutational signatures (SBS10c and SBS10d) were 
observed in normal and neoplastic crypts from individuals with 
germline POLD1 mutations. Both were characterized predomi-
nantly by C>A substitutions: in SBS10c at ACC, CCA, CCT, TCA 
and TCT trinucleotides and in SBS10d at TCA and TCT trinucleo-
tides (the mutated bases are underlined) (Fig. 2d,e, Extended Data 
Figs. 5–7 and Methods).
The increases in SBS burdens in normal intestinal crypts from 
POLE germline mutation carriers compared to healthy individuals 
were almost completely attributable to SBS10a, SBS10b and SBS28 
mutations, and in POLD1 mutation carriers to SBS10c mutations. 
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By contrast, the estimated burdens of SBS1, SBS5, SBS88 and SBS89 
found in normal intestinal crypts from POLE/POLD1 germline 
mutation carriers were similar to those expected in normal indi-
viduals of the same age. Thus, defective POLE/POLD1 proofread-
ing appears not to substantially affect the rates of the mutational 
processes underlying SBS1, SBS5, SBS88 and SBS89. POLE and 
POLD1 are responsible for leading and lagging strand DNA syn-
thesis, respectively1,2. Consistent with these roles, there was marked 
replication strand bias of SBS10a and SBS10b somatic mutations in 
POLE germline mutation carriers, with the opposite bias of SBS10c 
and SBS10d in POLD1 mutation carriers (Extended Data Fig. 7b).
The elevated mutation loads in adenoma and carcinoma crypts 
from POLE/POLD1 germline mutation carriers compared to nor-
mal intestinal crypts from each individual were also predominantly 
due to increased burdens of SBS10a and 10b (in POLE-mutant 
cases) and SBS10c and SBS10d (in POLD1-mutant cases) (Fig. 2f,g). 
However, crypts from POLE-mutant polyps showed greater relative 
increases in SBS10a than SBS10b compared to histologically normal 
POLE
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Fig. 1 | SBS and ID burdens in normal and neoplastic intestinal crypts from individuals with germline POLE or POLD1 mutations. a, Genome-wide 
mutation burden per individual, with the specific germline mutation indicated at the top and color coded (blue, red, green and purple denote POLE 
L424V, POLD1 S478N, POLD1 L474P and POLD1 D316N, respectively). For box-and-whisker plots, the central line, box and whiskers represent the median, 
interquartile range (IQR) from first to third quartiles, and 1.5 × IQR, respectively. b, Mean SBS burden versus age, showing regression lines for the four 
different germline mutations. The relationship between age and SBS burden in normal individuals is denoted by the dashed line. c, Genome-wide ID burden 
per individual. d, Relationship between age and ID burden. e, ID rate (per year) versus SBS rate (per year); the cross indicates the SBS and ID rate in normal 
individuals. f, ID and SBS burden in adenomatous samples from individuals with POLE/POLD1 mutations. The gray box indicates the range of mutation 
burdens in normal intestinal crypts from individuals with POLE/POLD1 mutations.
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POLE crypts (Fig. 2f,g). The mechanisms underlying these marked 
accelerations in mutation rates during neoplastic change, and why 
they apply differentially to the processes underlying the different 
signatures, are unknown.
Insertions and deletions in normal intestinal crypts from both 
POLE and POLD1 germline mutation carriers were dominated by 
single T insertions at T homopolymer tracts, characteristic of sig-


















































































































































































































Fig. 2 | Phylogenies of intestinal crypts with mutational signature annotation. a,b, Phylogenies of microdissected intestinal crypts of PD44587 (POLE 
L424V) (a), exhibiting mainly SBS10a and SBS10b, and PD44585 (POLD1 S478N) (b), exhibiting SBS10c. SBS1 and SBS5, normal signatures of aging, are also 
present. Signature exposures are color coded as indicated below the trees. Branch lengths correspond to SBS mutation burdens. c, In addition to mutagenesis 
due to POLE L424V, PD44592 shows widespread mutagenesis resulting from exposure to a platinum-based chemotherapeutic agent (SBS35-like).  
d,e, Probability distributions of SBS10c (d) and SBS10d (e), two novel signatures associated with POLD1 mutagenesis. f, Phylogeny of PD44589 (POLE 
L424V) containing samples from driver-bearing adenomas (*) and a carcinoma (c). Note that the y axis is broken for scale, preserving the original signature 
proportions. This individual showed mutagenesis due to exposure to capecitabine (capec, SBS17b-like), which was localized to carcinoma samples and 
nearby normal rectum (marked with r). g, Phylogeny of PD44584 (POLD1 S478N), with driver-bearing adenomas (*). One particular polyp showed  
extensive hypermutation (note broken y axis), largely due to SBS10d. 5FU/capec, capecitabine and fluorouracil. 5FU, 5-fluorouracil; capec, capecitabine.
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Fig. 3 | POLE and POLD1 mutagenesis in other tissues. a, Signature contribution to mutational landscapes of various tissues in individuals with a POLE L424V 
(PD44594, PD44593, PD44580, PD44589) or POLD1 S478N (PD44584, PD44582) germline mutation. Normal cerebral cortex, skeletal muscle, smooth 
muscle, artery, blood and sperm were sequenced using a modified duplex sequencing protocol, while other tissues were subjected to low-input WGS after 
laser-capture microdissection. Groups of mutational signatures are color coded as indicated. b, Estimated genome-wide total mutation rate per year for 
blood, sperm and endometrium (black dots), as well as yearly mutation burden due to SBS1 and SBS5 (gray dots with 95% CI). Mutation rates of normal 
controls for blood, sperm and endometrium31 are displayed for reference. c, Early embryonic SBS in individuals with a POLE L424V germline mutation, with 
a contribution from POLE signatures (blue, SBS10a, SBS10b and SBS28) and normal signatures (red, SBS1 and SBS5). M indicates that the mutation was 
inherited maternally, P paternally; M* indicates presumed maternal inheritance based on pedigree. P value is the result of a two-sided Wilcoxon rank-sum 
test on total counts of mutations attributed to SBS10a, SBS10b and SBS28. d, Early embryonic insertions of T at homopolymers of T (indicative of POLD1 
mutagenesis) in individuals with POLD1 germline mutations (S478N: PD44581, PD44582, PD44584, PD44585; L474P: PD44588; D316N: PD44590). 
Again, P and M indicate paternal and maternal inheritance, respectively. P value is the result of a two-sided Wilcoxon rank-sum test on total counts.
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crypts compared to normal crypts from each individual (Fig. 1c,f, 
Extended Data Fig. 8 and Supplementary Table 2).
Cancer driver mutations found in crypts from normal intestine, 
and colorectal neoplasms from individuals with POLE/POLD1 
germline mutations, showed SBS and ID mutational spectra similar 
to genome-wide spectra from normal intestinal crypts from these 
individuals (Extended Data Fig. 9a–c and Supplementary Table 3).
Mutagenesis in other tissues. Cancers of the colorectum and 
endometrium are the predominant types associated with germline 
and somatic POLE/POLD1 mutations16–18,50. Similar to intestinal 
crypts, endometrial glands are clones derived from a single, recent 
ancestral stem cell, and whole-genome sequencing of a gland 
reveals the mutations present in that ancestral cell31,51. Eleven 
endometrial glands dissected from a 60-year-old individual car-
rying a POLE L424V germline mutation showed elevated rates of 
SBS (148 versus 29 per year in healthy individuals) (Fig. 3b) and ID 
(6 versus <1 per year in normal individuals) (Supplementary Table 2). 
SBS10a and SBS10b were responsible for the increase in SBS 
rate compared to healthy individuals (Fig. 3a,b). Somatic driver 
mutations in cancer genes are common in normal human endo-






































































































































































Fig. 4 | Genome- and coding-sequence-wide increase in mutation burdens. a, Genome-wide proportion of mutations due to POLE and POLD1 germline 
mutations across various normal tissues. Colored bars indicate mutagenesis due to POLE (SBS10a, SBS10b, SBS28) or POLD1 (SBS10c, SBS28) mutational 
signatures, with normal signatures in gray (SBS1, SBS5 and, for skin, SBS7a and SBS7b). b, Protein-coding exome proportion of mutations due to POLE 
and POLD1 germline mutations across various normal tissues, showing a much lower increase in polymerase-related mutational signatures (Wilcoxon 
signed-rank test P = 6.1 × 10−5). c,d, Mutational and chronological ages of histologically normal intestinal crypts per individual. Mutational ages are 
calculated based on the expected rate of mutation accumulation in wild-type intestinal crypts28, enabling the calculation of both SBS and ID mutational 
age. Plots show SBS (c) and ID (d) mutational ages across the whole genome (filled dots) and coding genome (filled diamonds). Germline mutation is 
color coded: blue, red, green and purple denote POLE L424V, POLD1 S478N, POLD1 L474P and POLD1 D316N, respectively. Individuals’ chronological ages 
are indicated by unfilled circles, and UK life expectancy is displayed as a dashed horizontal line.
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all but one gland from this individual (Extended Data Fig. 9e and 
Supplementary Table 3).
To further investigate mutagenesis in other cell types and embry-
onic germ layers, we microdissected and sequenced fragments of 
various tissues from a 46-year-old individual with a germline 
POLE L424V mutation (PD44594). In skin epithelium, aging- and 
UV-related signatures were accompanied by substantial contribu-
tions from SBS10a and SBS10b. The VAFs of mutations generated 
from the remaining tissues indicated that they contained many cell 
clones, and thus mutation burdens and mutational signatures were 
difficult to assess (Supplementary Table 2). For these, we used a 
modified duplex sequencing protocol technique, termed NanoSeq53, 
to investigate the mutational processes present. By sequencing 
single DNA molecules at low error rates, this method allows quan-
tification of mutation burdens and signatures from tissues in which 
cells derived from many progenitors are intimately mixed, and 
clonal units for sequencing cannot be dissected (Methods). In all 
tissues we subjected to this method (smooth muscle, skeletal mus-
cle, arterial tunica and cerebral cortex), aging-related signatures 
were accompanied by SBS10a and SBS10b. Therefore, in all evalu-
able tissues from this individual, SBS10a and SBS10b were clearly 
observed, indicating that these tissues carry elevated mutation 
burdens (Fig. 3a).
Next, we assessed the mutational processes in blood and in sperm 
from four individuals—two with POLE L424V and two with POLD1 
mutations. All samples showed elevated total SBS rates compared 
with normal controls (Fig. 3a,b). Estimated yearly mutation rates 
due to SBS1 and SBS5 in blood and sperm were, however, con-
sistent with normal controls53 and previous estimates54,55, and the 
excess mutation burdens were, for the most part, due to SBS10a and 
SBS10b (POLE-mutant individuals) and SBS10c (POLD1-mutant 
individuals) (Fig. 3a,b).
Age-related clonal hematopoiesis (ARCH) is a common condi-
tion caused by a characteristic set of somatically acquired driver 
mutations56,57. To investigate the effect on ARCH of the elevated 
mutation rates caused by germline POLE and POLD1 muta-
tions, 22 blood samples from 14 individuals were sequenced to 
~10,000-fold coverage for ARCH-associated driver mutations58. No 
evidence of these was observed at the standard 2% VAF threshold. 
The results are consistent with previous observations that hemato-
logical malignancies are not part of the clinical spectrum observed 
in these individuals16–18 and support the broader clinical findings 
that, despite the elevated genome-wide mutation rate, individuals 
with POLE and POLD1 mutations do not show an increased fre-
quency of age-related phenotypes.
In summary, mutational signatures associated with POLE/POLD1 
exonuclease domain mutations were found in all cells from all tis-
sues examined and across the three germ layers. The elevation of 
burden was variable among tissues, being higher in intestinal crypts 
and endometrial glands than in other tissues. The results from 
sperm indicate that the elevated mutation rate extends beyond 
somatic tissues into the germline.
Mutagenesis during early embryogenesis. Somatic mutations 
accumulate throughout development, from the first cell division 
onwards59–62. A mutation arising in an early embryonic cell may 
be present in a substantial proportion of adult cells and in multi-
ple different tissues59. Early embryonic mutations can be detected 
in whole-genome sequences of highly polyclonal adult tissue 
samples as mutations with relatively high VAF59,60,62. Using this 
approach, putative early embryonic mutations were identified from 
whole-genome sequences of whole-blood samples. The embryonic 
mutational spectra of some POLE-mutant individuals exhibited sig-
nificantly larger exposures to SBS10a, SBS10b and SBS28 (P < 0.05, 
Wilcoxon rank-sum test), whereas others were dominated by SBS1 
and SBS5, the signatures normally responsible for early embryonic 
mutations62 (Fig. 3c). Similarly, in POLD1-mutant cases, the num-
ber of early embryonic single-base pair (bp) insertions was highly 
elevated in some, but not all, individuals (Fig. 3d). This heterogene-
ity reflects the inheritance pattern of the germline mutation and is 
probably a consequence of the maternal to zygotic transition of gene 
expression63. When a germline POLE/POLD1 mutation is pater-
nally inherited, any effect on mutagenesis is delayed until zygotic 
genome activation, thus sparing the early embryo for the first few 
cell divisions. When maternally inherited, however, the defective 
proofreading polymerase is present in the cytoplasm of the ovum 
and POLE/POLD1 mutagenesis therefore occurs immediately after 
fertilization, leading to a high prevalence of such mutations in 
early embryogenesis. These results indicate that mutagenesis due 
to defective POLE/POLD1 proofreading is present at the earliest 
stages of life.
Differential mutation burdens across the genome. We compared 
the distribution of somatic mutations across the genome to the 
mutation burden in the protein-coding exome in individuals with 
germline POLE/POLD1 mutations (Fig. 4a,b). Mutation burdens 
due to the various forms of SBS10 were heavily biased towards 
intronic, intergenic and late-replicating regions (Extended Data 
Fig. 7d,e), proportionately sparing protein-coding exons. This rela-
tively constrained increase in mutation burdens in protein-coding 
exons may conceivably mitigate the biological consequences of 
elevated somatic mutation rates due to POLE/POLD1 germline 
mutations. Nevertheless, differential burdens between tissues were 
maintained and mutation rates in coding regions were increased in 
colon and endometrium more than in skin (Fig. 4b).
Discussion
This study shows that multiple normal cell types from POLE/POLD1 
exonuclease domain germline mutation carriers demonstrate the 
mutational signatures and elevated somatic SBS and ID mutation 
rates characteristic of defective proofreading by these polymerases. 
The results are consistent with the presence of elevated mutation 
rates in all cells of all types throughout life.
The extent of the elevation in mutation rate appears greater in 
intestinal and endometrial epithelium than in the other cell types 
analyzed. The basis for this variation is not understood, but may 
reflect different stem cell division rates. It may also, at least in part, 
explain the predilection for colorectal and endometrial cancer 
observed in these individuals.
The somatic mutation theory of aging proposes that the increas-
ing somatic mutation burdens in normal cells, continuously accrued 
over a lifetime, have increasingly detrimental effects on cell func-
tion and thus engender the set of phenotypic features collectively 
termed aging19–24. The mutation burdens observed in cells from 
POLE/POLD1 mutation carriers are higher than those in normal 
individuals of the same ages. Therefore, POLE/POLD1 mutation 
carriers have elevated ‘mutational ages’ (Fig. 4c,d). The biological 
consequences of this generalized elevated mutational age appear, 
however, to be relatively limited. Other than the increase in inci-
dence of colorectal, endometrial and other neoplasms, phenotype 
information from more than 100 POLE/POLD1 mutation carriers 
does not obviously reveal features of premature aging or early onset 
of age-related, non-neoplastic disease, and many survive into the 
late decades of the standard human lifespan16–18 (Supplementary 
Table 1). Therefore, the rare natural experiment of germline 
POLE/POLD1 exonuclease domain mutations leading to elevated 
mutation rates does not support a simple somatic mutation the-
ory of aging. The results are, moreover, similar to those obtained 
in mice with engineered germline POLE and POLD1 exonuclease 
domain mutations10,11.
Important cautions, however, should temper this conclusion. 
First, more comprehensive measurement of somatic mutation 
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burdens across cell types in POLE/POLD1 germline mutation car-
riers is indicated. The varying degrees of mutation rate elevation 
between cell types potentially leaves some—which could be par-
ticularly influential in generating the aging phenotype—relatively 
protected. Second, POLE/POLD1 exonuclease domain germ-
line mutation carriers show burdens of somatic copy number 
changes, rearrangements and telomere erosion similar to normal 
individuals (Supplementary Table 2 and Supplementary Note). If 
aging depends on these mutation classes, it would not be acceler-
ated in POLE/POLD1 mutation carriers. Finally, additional factors 
may mitigate the impact of elevated mutation burdens in 
POLE/POLD1 exonuclease domain carriers. For example, a dis-
proportionately small fraction of the mutation burdens due to 
SBS10a,b,c,d falls in coding regions of the genome, potentially 
reducing its biological impact64.
Nevertheless, the results indicate that many normal human cell 
types throughout life tolerate high SBS and ID mutation rates and 
therefore that the direct effects of somatic mutation accumulation 
may not underlie all components of the progressive biological dys-
function termed aging.
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Methods
Ethical approval and study participants. This research complies with all relevant 
ethical regulations. Patients were recruited as part of the CORGI 2 study, United 
Kingdom Research Ethics Committee (REC) no. 17/SC/0079. Additional sample 
collection was undertaken under approval from the following committees: London, 
Westminster; North East, Newcastle and North Tyneside 1; and NRES Committee 
East of England, Cambridge South (REC nos. EC04/015, 16/NE/003 and 07-MRE05-
44, respectively). Informed consent was obtained from all participants and no 
monetary compensation was offered for their participation. A complete list of study 
participants and tissue samples is summarized in Supplementary Tables 1 and 2.
DNA extraction from bulk samples. Frozen whole blood underwent DNA 
extraction using the Gentra Puregene Blood Kit (Qiagen). Briefly, 1–2 ml of 
frozen blood was thawed, lysed in RBC lysis solution and centrifuged. Cell pellet 
was resuspended in cell lysis solution and incubated at 37 °C for 2 h. RNA and 
protein were degraded using RNase A solution and protein precipitation solution, 
respectively. DNA was precipitated with isopropanol, and was extracted from semen 
samples using β-mercaptoethanol followed by phenol chloroform extraction65.
Tissue preparation. Tissues were embedded in Optimal Cutting Temperature 
compound, and frozen histological sections were cut at 30 µm, mounted on 
polyethylene naphthalate (PEN) slides and fixed in 70% ethanol for 5 min, 
followed by two washes with PBS for 1 min each. Slides were manually stained in 
hematoxylin and eosin (H&E) using a conventional staining protocol. A subset of 
samples (PD44594c–h and PD44589f) were fixed in PAXgene Tissue FIX (Qiagen) 
according to the manufacturer’s instructions. Fixed tissue samples were embedded 
in paraffin using a Tissue-Tek tissue-processing machine (Sakura). No formalin 
was used in the preparation, storage, fixation or processing of samples. Processed 
tissue blocks were embedded in paraffin wax, sectioned to 10-µm thickness and 
mounted onto PEN slides (Leica). Tissue slides were stained using a standard H&E 
protocol. Slides were temporarily coverslipped and scanned on a NanoZoomer 
S60 Slide Scanner (Hamamatsu); images were viewed using NDP.View2 software 
(Hamamatsu).
Laser-capture microdissection. Laser-capture microdissection was undertaken 
using a LMD7000 microscope (Leica) into a skirted 96-well PCR plate. Cell 
lysis was undertaken using 20 µl of proteinase-K PicoPure DNA Extraction kit 
(Arcturus), and samples were incubated at 65 °C for 3 h followed by proteinase 
denaturation at 75 °C for 30 min. Thereafter samples were stored at −20 °C before 
DNA library preparation.
Intestinal crypt isolation. Crypts from one tissue block (PD44593e) were isolated 
using EDTA chelation. In brief, dissected mucosa was incubated in an EDTA 
solution and gently agitated, resulting in dissociation of intestinal crypts from the 
underlying components of the intestinal epithelium. Crypts were then separated 
under a light microscope and placed in ATL buffer (Qiagen) containing 10% (v/v) 
proteinase K and digested overnight at 56 °C. DNA extraction was performed using 
the QiaAMP DNA micro kit (Qiagen) as per the manufacturer’s instructions; DNA 
was then stored at −20 °C.
Low-input DNA library preparation and sequencing. DNA library preparation 
of microdissected tissue samples was undertaken as previously described, 
using a bespoke low-input enzymatic-fragmentation-based library preparation 
method28,29,31,66. This method was employed as it allows for high-quality DNA 
library preparation from a very low starting quantity of material (100–500 cells). 
DNA library concentration was assessed after library preparation and used to 
guide the choice of samples to take forward to DNA sequencing. Minimum library 
concentration was 5 ng µl–1, and libraries with >15 ng µl–1 were preferentially 
chosen; 150-bp, paired-end Illumina reads were prepared with Unique Dual Index 
barcodes (Illumina).
DNA sequencing was undertaken on a NovaSeq 6000 platform using the XP kit 
(Illumina). Samples were multiplexed in pools of 6–24, then sequenced to achieve 
a coverage of ≥30×.
Mutation calling and postprocessing filters. Sequencing reads were aligned to 
NCBI human genome GRCh37 and aligned using Burrows–Wheeler alignment 
(BWA-MEM). SBS were called using the algorithm cancer variants through 
expectation maximization67. Mutations were called using an unmatched normal 
synthetic bam file to retain early embryonic and somatic mutations. Postprocessing 
filters were applied to remove low-input, library-preparation-specific artifacts 
and germline mutations using a previously described method30,31,62,66. Filters 
applied: (1) common single-nucleotide polymorphisms (SNPs) were removed by 
filtering against a panel of 75 unmatched normal samples68; (2) to remove mapping 
artifacts, mutations were required to have a minimum median read alignment 
score of mutant reads ≥140, and fewer than half of the reads supporting the 
mutation should be clipped (clipped median = 0); (3) a filter was utilized to remove 
overlapping reads resulting from relatively short insert size, which could lead to 
double counting of variant reads; and (4) a filter was used to remove cruciform 
DNA structures that can arise during the low-input library preparation method.
Next, we applied multiple filters to remove germline variants and potential 
artifacts whilst retaining bona fide embryonic and somatic variants. This approach 
has been detailed in previous publications, and the code for these filters can be 
found at https://github.com/TimCoorens/Unmatched_NormSeq. Mutations 
were aggregated per patient, and a read pile-up was performed using an in-house 
algorithm (cgpVAF) to tabulate the read count of mutant and reference reads per 
sample for each mutation locus. Germline mutations were filtered out using an 
exact binomial test, which is used to distinguish germline from somatic variants 
and utilizes aggregate read counts from all samples of the same patient30,62. In 
brief, the read depth across all samples from that individual was calculated 
(median in this study, ~340×). This high coverage yields a very precise estimate 
of the true VAF of each mutation. While the VAF estimates of the earliest 
embryonic single-nucleotide variants (SNVs) and germline variants from samples 
sequenced at 30× might overlap, VAFs from the aggregate coverage from that 
individual (~340×) are distinguishable using statistical testing. To achieve this, the 
beta-binomial test was applied using the overdispersion parameter (ρ) threshold 
for genuine variants of ρ > 0.1.
Phylogenetic trees were created using MPBoot (v.1.1.0 bootstrapped, 1,000) 
and mutations were mapped to branches using maximum-likelihood assignment.
Indels were called using Pindel69 utilizing the same synthetic unmatched 
normal sample employed in SBS mutation calling. ID calls were filtered to remove 
those with a quality score of <300 (‘Qual’; sum of mapping qualities of the 
supporting reads) and a read depth of <15. Thereafter, ID filtering was performed 
in a similar manner to that of SBS, to remove germline variants and library 
preparation/sequencing artifacts.
Copy number alteration calling. Somatic copy number variants (CNVs) 
were called using the algorithm allele‐specific copy number analysis of tumors 
(ASCAT)70 (https://github.com/Crick-CancerGenomics/ascat) in the ascatNGS 
package71. Bulk (blood or, in one case, tissue) samples were used as matched 
normals. ASCAT was initially run with default parameters. To reduce the number 
of false-positive calls that arise in normal tissue samples, a segmentation penalty 
was applied in the ASCAT ‘aspcf ’ step. Optimum performance was observed with a 
penalty value of 100, which was subsequently applied to all samples. Copy number 
calls were further filtered to remove artifacts. Copy number (CN) calls <2 MB 
were excluded. Samples with a goodness-of-fit of <95% were excluded. CN calls at 
specific recurrent breakpoints were removed. Sharing of CNVs between samples 
from different tissue blocks and across individuals that violated phylogenetic 
structures implied from SBS and ID phylogenetic trees was treated as artifactual 
and removed from analysis. Similarly, any recurrent copy number calls with 
identical breakpoints that were observed across different individuals were also 
removed. CNV calls were manually verified by visualization of reads in JBrowse72.
Structural variant calling. Whole-genome sequences were analyzed for somatic 
structural variants (SVs) using the algorithm breakpoints via assembly (BRASS)73; 
paired blood samples were used as controls. If no blood sample was available, a tissue 
sample was used that was phylogenetically distant to the sample under analysis. SV 
calls were filtered using an in-house algorithm in a multistage process using bespoke 
software (https://github.com/MathijsSanders/AnnotateBRASS). Finally, all SV calls 
were manually inspected to confirm somatic variants. SV calls in L1 transposon 
donor regions and fragile sites were excluded from the final SV analysis.
Mutational signature analysis. The R package HDP (https://github.com/
nicolaroberts/hdp), based on the hierarchical Dirichlet process74, was used to 
extract mutational signatures. Analysis of mutational signatures using this package 
has previously been applied to normal tissues28–31. In brief, this nonparametric 
Bayesian method models categorical count data using the hierarchical Dirichlet 
process. A hierarchical structure is established using patients as the first tier 
(parent nodes) and individual samples as the second tier (dependent nodes). 
Uniform Dirichlet priors were applied across all samples. The algorithm creates a 
mutation catalog for each sample and infers the distribution of signatures in any 
one sample using a Gibbs sampler. We performed mutational signatures analysis 
per branch, counting each branch of the phylogenetic tree as a distinct sample to 
avoid double counting of mutations. Since the Markov chain Monte Carlo process 
scales linearly with the number of counts, we randomly subsampled each branch 
to a maximum of 2,500 total substitutions. Branches with <100 mutations were 
excluded from the mutational signature extraction. No reference signatures were 
included as priors.
To assess the contribution of each mutational process, mutational signatures 
were refitted to all mutation counts of branches of phylogenies using the R package 
sigfit (https://github.com/kgori/sigfit)75. To avoid overfitting, a limited subset of 
reference mutational signatures were included per patient corresponding to the 
HDP signatures identified in that individual. In the case of SBS10d, it was fitted 
only to branches in which an exposure had originally been reported.
Further details of mutational signature extraction, validation and mutational 
signature assignment are included in the Supplementary Note.
Cancer driver mutations. Cancer driver mutations were identified using two 
methods aiming to identify genes and mutations in this cohort that are subject 
NATuRE GENETICS | www.nature.com/naturegenetics
Articles Nature GeNetics
to positive selection. Firstly, to identify mutations in cancer genes under positive 
selection in an unbiased manner, we ran a modified dNdS method76. To avoid 
double counting of mutations, only unique mutations (SBS and ID) mapped 
to branches of the phylogenetic trees were analyzed. dndscv was run using the 
following parameters: max_coding_muts_per_sample=5000 and max_muts_per_
gene_per_sample=20. The mutational processes associated with defective DNA 
polymerases have a well-reported extended sequence context bias8,76 that alters the 
expected probability of observing a mutation in specific trinucleotide nucleotide 
contexts. To account for this bias, a modified dNdS method was applied. Global 
dNdS values for the expected number of each mutation type were replaced with 
corrected values taking into account the observed mutation subtype (synonymous, 
missense, nonsynonymous and splice site) totals. A generalized negative binomial 
linear model was applied to each mutation subtype accounting for the biased 
distribution observed. P values were combined using Fisher’s method, and multiple 
testing correction was performed with the Benjamini–Hochberg method. Genes 
with qval < 0.05 were considered to be under positive selection.
A second phase of cancer gene mutation analysis was undertaken, identifying 
mutations in this cohort that are codified in cancer mutation databases and exhibit 
characteristic traits of cancer driver mutations, an approach previously employed 
in the study of normal tissues30,31. In this phase of the analysis we sought to identify 
the spectrum and frequency of cancer driver mutations in this cohort. Somatic 
mutations (SBS and ID) were collated per sample from all tissues. Analysis was 
restricted to protein-coding regions, and mutations were filtered using lists of 
known cancer genes; mutations in samples from intestinal epithelium were filtered 
using a list of 90 genes associated with colorectal cancer28; samples from all other 
tissues, including blood, were filtered using a pan-cancer list of 369 driver genes76. 
Genes were then characterized according to their predominant molecular behavior: 
dominant, recessive or intermediate (those demonstrating aspects of both types of 
behavior) using the COSMIC Cancer Gene Census77. All candidate mutations were 
annotated using the cBioportal MutationMapper database (https://www.cbioportal.
org/mutation_mapper). Mutations meeting the following criteria were considered to 
be driver mutations: truncating mutations (those causing a shortened RNA transcript, 
nonsense, essential splice site, splice region and frameshift ID) in recessively acting 
genes; known activating hotspot mutations in dominant (and recessive) genes; 
and, lastly, mutations in neither of the above categories but characterized by the 
MutationMapper database as being ‘likely oncogenic’ were also included in the 
final driver mutation catalog. We also sought to compare the frequency of driver 
mutations in histologically normal crypts with POLE and POLD1 mutations to those 
from individuals not carrying DNA polymerase mutations. Somatic mutations from 
445 normal intestinal crypts28 were annotated and filtered using the above criteria. 
Comparison was made with normal intestinal crypts from this cohort of individuals 
with POLE and POLD1 germline mutations (Extended Data Fig. 3).
Embryonic variant calling. Whole-genome sequencing of bulk blood samples 
was used to identify early embryonic SBS and ID mutations. Since bulk blood 
represents a very polyclonal tissue, variants found in blood reflect those generated 
in the first few cell divisions of life62. Variant counts from blood samples were 
included in the germline and artifact filtering, as described above. For SBS, a 
minimum VAF of 0.15 was required to be included in the embryonic set. Of the 
remaining SBS, 205 out of a total 385 (53%) were shared with intestinal samples, 
confirming they must have arisen before gastrulation. For ID, we set the minimum 
to 0.1 to reflect the higher levels of noise accompanying indel calling and variant 
read counting. For indels, this amounted to 28 out of 30 (93%) mutations.
To investigate the role of POLE mutagenesis in the early embryo, we used the 
mutational signature contribution to the observed SBS counts, given the highly 
elevated SBS mutation rate. We fitted SBS1, SBS5, SBS10a, SBS10b and SBS28 to 
patient-specific embryonic counts using SigFit. SBS1 and SBS5 reflect the normal 
background mutagenesis already present in the embryo60,62, while the other 
signatures are caused by defective POLE.
For POLD1 mutagenesis, we quantified the number of insertions of T at 
homopolymers of T, the characteristic peak in ID1 and the one dominating the 
indel landscape in patients with POLD1. We used insertions rather than SBS 
because of the relatively modest increase in SBS mutation rate, but a much higher 
increase in the rate of insertion acquisition.
Modified duplex sequencing. DNA from bulk blood and sperm samples from four 
individuals with germline POLE and POLD1 mutations was extracted as outlined 
above. Samples from normal healthy controls were obtained and processed using 
the following method. Whole blood was diluted with PBS, and mononuclear 
cells (MNC) were isolated using lymphoprep (STEMCELL Technologies) density 
gradient centrifugation. The red blood cell and granulocyte fraction of the blood 
was then removed. The MNC fraction was depleted of red blood cells by lytic 
steps involving three incubations at room temperature for 20, 10 and 10 min, 
respectively, with RBC lysis buffer (BioLegend). DNA was extracted from sperm 
samples from a 21-year-old donor.
Our modified duplex sequencing method, called NanoSeq, relies on blunt-end 
restriction enzymes to fragment the genome to avoid errors associated with the 
filling of 5' overhangs and the extension of internal nicks during end repair after 
sonication. Our modified method has error rates <1 × 10–8 (ref. 53).
Sperm NanoSeq libraries from POLE/POLD1 mutants (median insert sizes of 
289 bp) were sequenced as 150-bp paired-end reads on NovaSeq, resulting in 2.06–
2.32 × 10–8 paired-end reads (20–23× coverage) and 2.5–3.2 × 109 duplex calls (~1× 
effective coverage). Multiple replicates of sperm (n = 7) and blood/granulocyte 
(n = 6) NanoSeq libraries from healthy donors were sequenced to higher depth, 
resulting in 1.5–1.6 × 109 paired-end reads (150–160× coverage) and 1.5–2.5 × 1010 
bp calls (5–8× effective coverage).
Given the uneven frequencies of trinucleotides in the digested genome, the 
strong filtering of common SNP sites (typically occurring at CpG) and the strong 
dependence of mutation rates on trinucleotide contexts, our estimates of mutation 
burdens are normalized and projected onto genomic trinucleotide frequencies.
Let t denote the count of a given trinucleotide of type i = 1,…,32. The 
frequency of each trinucleotide is calculated separately for the genome fgi and for 









There are j = 1,…,classes of substitution where the mutated base is a 
pyrimidine. Let sij denote the count of substitution j in trinucleotide context i, 
giving a total of 96 substitution classes. Each substitution count is corrected as 
follows:
s′ij = sijri
The corrected substitution counts provide a substitution profile projected onto 










Sequencing for ARCH-related variants in blood. Twenty-two blood samples 
were subjected to deep targeted sequencing (median coverage ~10,000×) using a 
gene panel of known drivers of clonal hematopoiesis58. Samples were sequenced 
on Illumina Hiseq4000 lanes using 75-bp paired-end reads. Sequencing reads 
were aligned to the human reference genome (GRCh37d5) using the BWA aligner. 
ShearwaterML27 was used to call somatic SNVs. This algorithm was developed 
to detect subclonal mutations in deep-sequencing data, by modeling the error 
rate at each site using information from the panel of normal unrelated samples. 
The normal panel we employ comprises data from 310 previously sequenced 
normal individuals (with no identifiable ARCH mutations) aged 42–89 years. 
Postprocessing filtering was performed as previously described, with a requirement 
for variants to have at least two supporting reads in both directions27. Germline 
variants were excluded by removal of those with VAF > 0.42. Probable false 
positives were removed by exclusion of variants with VAF < 0.005. Further filtering 
restricted analysis to variants causing nonsynonymous protein-coding changes or 
introducing a stop codon.
Mutation burden in coding regions and mutational age calculations. The 
mutational ages shown in Fig. 4c,d were calculated by assessing the per-block 
mutation rate for normal intestinal crypts across the whole-genome and 
coding regions; average mutation rates were then calculated per individual for 
the whole-genome and coding regions. These calculations were repeated for 
individuals from a cohort of wild-type crypts28, generating an expected mutation 
rate for the whole-genome and coding regions. The relative increase of the 
observed mutation rate in individuals with DNA polymerase mutations versus 
wild-type crypts was used to generate mutational age.
Telomere length estimation. Telomere attrition is a hallmark of cellular aging 
and is accelerated in certain disease processes. To assess the length of telomeres in 
the tissue samples in this cohort, we undertook estimation using two established 
methods from next-generation sequencing data.
Telomerecat is a ploidy-agnostic method of telomere length estimation (to bp 
resolution) from next-generation sequencing data that have been benchmarked 
across human and animal studies in normal tissues and cancers78. This method has 
been employed in previous studies of somatic mutations in normal mutations28–30. 
We generated telomere length estimates for all samples using 100 simulator runs 
(parameter -N100). Results for most, but not all, samples were plausible and 
showed a positive correlation with those from a second telomere length content 
algorithm (TelomereHunter). Approximately 30% of samples returned zero 
values for telomere length; similar observations have been made in other datasets 
sequenced on the Illumina NovaSeq platform. Results of the algorithm based on 
sequencing data generated by Illumina X10 and other sequencing platforms do 
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not demonstrate this pattern, and can be relied upon. For this analysis we favored 
TelomereHunter, which is a well-established method used in tumor sequencing 
analyses79, shows good concordance with other methods of telomere length 
estimation80 and is reliable across all tested samples sequenced on the Illumina 
NovaSeq platform.
Telomere content measurements were generated by running TelomereHunter 
using default parameters across all histologically normal crypts in this cohort 
(n = 109) and normal crypts from a previous study that do not have DNA 
proofreading polymerase germline mutations (n = 445)28. To assess age-related 
telomere attrition in normal tissues, we fitted a linear mixed-effects model to assess 
the effect of age and also to test whether telomere attrition is greater in crypts 
with a DNA proofreading polymerase mutation. Age was fitted as a fixed effect 
and patient as a random effect; an additional dichotomous genotype variable was 
added as a fixed effect. We assume a similar length at birth, and thus fitted a fixed 
intercept and assessed the difference in slope between samples from this cohort 
and nonpredisposed crypts. We compared the model fit using analysis of variance 
and the difference between models using a chi-squared test. P-value thresholds of 
>0.05 were used (Supplementary Note)
Research involving human gametes. Samples containing human gametes (sperm 
samples), collected under informed research consent from individuals enrolled in 
the CORGI v.2.0 study, were included in this manuscript. The CORGI v.2.0 study 
is approved by the United Kingdom NHS Research Ethics Committee (no. 17/
SC/0079). Sperm samples were studied using genome sequencing. All experiments 
were conducted in accordance with the relevant international and national 
standards. No modification or cloning of gametes was performed.
Reporting Summary. Further information on research design is available in the 
Nature Research Reporting Summary linked to this article.
Data availability
DNA sequencing data are deposited in the European Genome-Phenome Archive 
(EGA) with accession code EGAD00001006212. DNA sequencing data from 
the modified duplex sequencing are deposited in the EGA with accession code 
EGAS00001004066. Somatic mutations and mutational signature data from this 
cohort are available online (https://github.com/TimCoorens/Polymerase). All other 
data are available from the authors on request. The cBioPortal MutationMapper 
database was accessed at: https://www.cbioportal.org/mutation_mapper?standalon
eMutationMapperGeneTab=ATM.
Code availability
Code required to reproduce the analyses in this paper is available online. 
Mutation-calling algorithms are available through GitHub (https://github.com/
cancerit). All custom code used in this study is available online (https://github.
com/TimCoorens/Polymerase). Code for statistical analyses is provided in 
Supplementary Note.
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Extended Data Fig. 1 | Mutational signatures and structural variants in normal tissue from an individual exposed to oxaliplatin chemotherapy. Mutational 
signatures identified in normal intestinal crypts from individual PD44592 who had previously undergone treatment with oxaliplatin. Distinctive SBS and 
DBS signatures were observed that have previously been associated with oxaliplatin treatment in cancer samples. Unexpectedly high numbers of structural 
variants were also observed in the normal intestinal crypts from this individual and may be due to chemotherapy exposure. (a) Phylogenetic tree from 
individual PD44592 with structural variants (SVs) mapped to branches. Shapes correspond to SV type; translocation (circle), inversion (hexagon), large 
duplication (square) and deletion (triangle). Ordering of SVs and positioning along branches is arbitrary (b) SBS signature SBS35-like displayed above the 
Pan-Cancer Analysis of Whole Genomes (PCAWG) reference signature SBS35 (PCAWG)9 and E-SBS2048 (c) Doublet Base Substitution (DBS) signature 
displayed above PCAWG reference signature DBS5 and E-DBS5 from Pich et al 201948. (d-e) Cosine similarity matrices for SBS and DBS signatures.
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Extended Data Fig. 2 | Trisomy X (47XXX) with mosaic trisomic rescue in individual PD44587 identified by lineage tracing of somatic mutations. 
B-allele frequencies (BAF) of SNP sites for intestinal crypts with two copies of the X-chromosome (a) or three (b). Seven crypts exhibited the disomy, 
whereas one crypt and the majority of blood showed the trisomy. (c) The mean BAF of SNPs for samples with a disomic profile versus those with a 
trisomic profile. SNPs clustered in six distinct groups: those absent from all samples (marked with ‘1’), homozygously present across all samples (2), 
heterozygous in disomy but in one out of three copies in trisomy (3), heterozygous in disomy but on two copies in trisomy (4), absent from disomy but 
on one copy in trisomy (5) or homozygous in disomy but on two copies in trisomy (6). The last two clusters are inconsistent with an acquired gain of 
chromosome X, as they constitute bringing in novel germline SNPs or omission of those previously homozygotic. (d) Therefore, this profile can only be 
explained by a zygote which possessed three copies of X, one of which was mosaically lost in the crypt lineage.
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Extended Data Fig. 3 | Protein coding mutations due to mutational signatures of defective DNA polymerases. (a) Mutation burden per intestinal crypt 
per year of life. For box and whisker plots, the central line, box and whiskers represent the median, inter-quartile range (IQR) from 1st to 3rd quartiles and  
1.5 times the IQR. Elevated burdens of nonsense, missense and frameshift mutations are observed in crypts due to DNA polymerase associated mutational 
signatures. P-values result from two-sided Wilcoxon rank sum test. (b) Comparison of driver mutation burden of normal crypts from individuals with a 
germline DNA polymerase mutation (blue) and wild-type crypts (red). SBS mutations included are from n = 445 wild-type intestinal crypts28 and n = 109 
DNA polymerase mutant crypts from the current cohort. (c) Comparison of driver mutations normalised by the total number of protein coding mutations. 
Normalised proportion of driver mutations is displayed on the x-axis. No statistically significant difference in the driver mutation burden between DNA 
polymerase mutant and DNA polymerase wild-type crypts is observed (Chi-squared test p > 0.05).
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Extended Data Fig. 4 | Phylogenetic trees constructed from somatic single base substitution (SBS) mutations annotated with mutational signature 
exposure. Phylogenetic trees generated from normal and neoplastic crypts displayed per individual. Mutational signature exposure per branch is displayed 
as stacked bar plots. Ordering of mutational signatures within branches is arbitrary. SBS burden is displayed on the x-axis. Each tip represents a normal 
intestinal crypt unless otherwise indicated microbiopsies from; ‘s’ skin, ‘cc’ cerebral cortex, ‘oe’ oesophagus, ‘f’ hair follicle and ‘*’ indicates adenomatous 
crypts. Trees are grouped according to germline DNA polymerase mutation; (a) POLE L424V, (b) POLD1 S478N, (c) POLD1 L474P and (d) POLD1 D316N.
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Extended Data Fig. 5 | See next page for caption.
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Extended Data Fig. 5 | Characterisation of mutational signature SBS10c. (a) SBS mutational profiles for representative samples (PD44581b_lo0001, 
PD44585b_lo0009 and PD44582b_lo0001). (b) Histograms of Variant Allele Fraction (VAF) for SBS mutations in each sample. (c) JBrowse images 
showing SBS10c mutations validated across multiple samples. Matched normal samples are displayed at the bottom of each image (d) Mutational profile 
showing replication strand bias of SBS10c mutations from a representative sample. Coloured bars indicate the mutation count on the leading strand 
and light grey bars indicate the lagging strand. (e) Barplot of SBS mutations assigned to SBS10c on the transcribed (T) and un-transcribed (U) strands, 
p-values were calculated for each mutation type using a two-sided Poisson test, statistically significant p-values are displayed.
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Extended Data Fig. 6 | See next page for caption.
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Extended Data Fig. 6 | Characterisation of mutational signature SBS10d. (a) SBS mutational profiles for samples (PD44584c_lo0001, PD44584c_
lo0002 and PD44584c_lo0003). (b) Histograms of Variant Allele Fraction (VAF) for SBS mutations in each sample. (c) JBrowse images showing clonal 
SBS10d mutations validated across multiple samples. (d) Mutational profile showing replication strand bias of SBS10d mutations from a representative 
sample. Coloured bars indicate leading strand and light grey bars indicate lagging strand. (e) Barplot of SBS mutations assigned to SBS10d on the 
transcribed (T) and un-transcribed (U) strands, p-values were calculated for each mutation type using a two-sided Poisson test, statistically significant 
p-values are displayed.
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Extended Data Fig. 7 | Characterisation of replication strand bias and extended sequence context of mutational signatures associated with germline 
DNA polymerase mutations. (a) Extended sequence context of mutations assigned to signatures SBS10a, SBS10b, SBS10c and SBS10d displayed with 
pyrimidine annotation. Plots show extended sequence context of C > A and C > T mutations in SBS10a and SBS10b respectively and C > A mutations in 
SBS10c and SBS10d. (b) Replication strand biases of SBS mutations indicated by excess mutations (annotated by pyrimidine base) on either the leading 
or lagging DNA strand. Biases are displayed according to mutations assigned to known signatures SBS10a and SBS10b and new signatures SBS10c and 
SBS10d. Only SBS mutations with an assignment probability >0.7 were included (Supplementary Methods). Strong replicative strand asymmetries are 
seen in known (SBS10a & SBS10b) signatures as well as new signatures; SBS10c and SBS10d. P-values were calculated using two-sided Poisson tests 
and corrected for multiple testing using the Benjamini-Hochberg method. Mutation types with statistically significant replication strand bias (adjusted 
p < 0.0001) are annotated with ‘****’. (c) ID replication strand asymmetries are displayed for single base insertions and deletions according to the affected 
polymerase gene; POLE (left) POLD1 (right). Replication strand bias is indicated by excess mutations with single base insertions on the leading strand 
in POLE mutant cells and on the lagging strand in POLD1 mutant cells. (d) Frequency of somatic SBS mutations assigned to each mutational signature 
SBS10a-d in replication timing bins. (e) Distribution of SBS mutations across different genomic regions; exonic, intronic and intergenic.
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Extended Data Fig. 8 | Phylogenetic trees constructed from somatic insertion and deletion (ID) mutations from normal and neoplastic intestinal 
stem cells. Phylogenetic trees generated from ID mutations. ID mutation burden is displayed on the y-axis. Each tree represents samples from a single 
individual. Trees are grouped according to germline DNA polymerase mutation (a) POLE L424V (b) POLD1 S478N (c) POLD1 L474P (d) POLD1 D316N.
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Extended Data Fig. 9 | See next page for caption.
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Extended Data Fig. 9 | Driver mutation landscape in normal tissues from individuals with POLE and POLD1 germline mutations. Driver mutations in 
tissues from individuals with germline DNA polymerase mutations. (a) Trinucleotide mutational spectrum of SBS driver mutations from normal and 
neoplastic cells showing characteristic peaks associated with DNA polymerase mutational signatures. (b) ID mutation spectrum showing ID type of 
driver mutations are associated with ID1 mutational signature. (c) Frequency of SBS driver mutations from normal and neoplastic cells according to their 
assigned mutational signature. (d) Cancer driver mutations (top 10) identified in histologically normal intestinal crypts displayed in order of frequency, 
mutation class is indicated by the colour. (e) Phylogenetic tree of SBS mutations from endometrial glands from individual PD44589. SBS driver mutations 
are plotted on the tree, ordering of the drivers within each branch is arbitrary. Driver mutation class is represented by the symbol: nonsense mutations 
(circles) missense (squares). Gene name and protein change are displayed above each symbol.
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